New Drug Discovery in Taiwan and Impressions in Pharmacy between Japan and Taiwan

Abstract

Taiwan’s new drug development has progressed significantly due to advances in biotechnology, policy support, and industry-academia collaboration. Key areas include antibody-drug conjugates, AI-driven drug design, novel chemical entities, and innovative drug formulations. Government initiatives like the precision health strategy and 505(b)(2) regulatory pathway have attracted investment and accelerated clinical development. Successes in rare diseases, oncology, and long-acting formulations showcase Taiwan’s growing global competitiveness. Looking forward, strengthening international collaboration, intellectual property strategy, and talent cultivation will be essential for sustaining momentum and advancing Taiwan’s pharmaceutical industry to the next level. Pharmacy education in Japan and Taiwan each has its own strengths-Japan emphasizes practical experience and attention to detail, while Taiwan focuses on flexibility and interdisciplinary learning. Through mutual exchange, students can broaden their global perspective and humanistic qualities. In the future, combining the strengths of both systems may cultivate outstanding pharmacy professionals with solid theoretical foundations and practical skills.